NCT00519480 - A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 11, 2007

Primary Completion Date

April 1, 2008

Study Completion Date

April 1, 2008

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

GSK189075

GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.

DRUG

Metformin

Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.

DRUG

Placebo

Placebo will be available as an oral tablets.

Trial Locations (4)

GSK Investigational Site, Buenos Aires

GSK Investigational Site, Berlin

GSK Investigational Site, Miami

GSK Investigational Site, San Antonio